Jeanne Davis
Nurse Practitioner · Troy, NYNPI 1619477171
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,783 of the $18,529 with a category attached, or 85.2%. It is spread thinly across 35 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 599 payments — averaging $30.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$4K
- Johnson & Johnson$2K
- AbbVie$2K
- Axsome Therapeutics, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- plus $6K from 29 others
What the payments were for
- Speaking & faculty fees$2,20012%
- Travel & lodging$3822%
- Food & beverage$15,78385%
- Education$1641%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,529 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 13 | $18,474 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,241 |
| Lisdexamfetamine Dimesylate | 16 | $3,119 |
| Lurasidone Hcl | 11 | $2,639 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $2,313 |
| Duloxetine Hcl | 23 | $778 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 25 | $576 |
| Bupropion XlBupropion Hcl | 31 | $489 |
| Oxcarbazepine | 15 | $449 |
| Quetiapine Fumarate | 28 | $429 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 28 | $390 |
| Fluoxetine Hcl | 26 | $382 |
| Sertraline Hcl | 27 | $314 |
| Buspirone Hcl | 18 | $272 |
| Clonazepam | 27 | $267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,180 | $18,47413 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $122 | $4,24111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in Troy
- Patricia BradtTroy$9K
- Patricia McGoldrickNew York$202K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
- Kerry AhernEast Syracuse$55K
- Valerie StanleyAlbany$55K
- Jodi LogerfoNew York$48K
- Grace WlasowiczRochester$41K
- Melissa LevinElmhurst$34K
- Carla JungquistCanandaigua$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.